Johnson & Johnson Backs HRS Registry to Advance Real-World Evidence in PFA

Irvine, CA – December 19, 2025 – Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced its sponsorship of a new data collection platform developed by the Heart Rhythm Society (HRS) to capture real-world data on pulsed field ablation (PFA) procedures used to treat atrial fibrillation (AFib). The first-of-its-kind registry will serve as a long-term data collection platform to evaluate clinical outcomes, support evidence-based practice, and inform the evolution of treatment strategies in electrophysiology.

“We’re sponsoring this registry to enable real-world data generation at scale across the industry to shape the future of AFib ablation. By complementing our own evidence-generation registries and studies with this data platform, we aim to shape best practices, guide continued innovation and ultimately improve outcomes for more people living with AFib,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, Johnson & Johnson MedTech. “This effort reflects our long-standing commitment to partnering with the clinical community and strengthening scientific understanding, a dedication grounded in our decades of scientific expertise and leadership in electrophysiology.”

Johnson & Johnson MedTech is committed to advancing the science of PFA and driving progress in arrythmia care, building on our leadership and an unwavering dedication to enhance healthcare through rigorous scientific inquiry and clinical excellence in electrophysiology. This commitment is reflected in our comprehensive, fully integrated portfolio of imaging, mapping, and ablation technologies -including versatile PFA platforms- designed to deliver safe, precise, and consistent outcomes to support procedures across a wide range of patient needs.

Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit biosensewebster.com.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to Collaborative Outcomes Registry for Evidence in Ventricular Arrhythmias. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

© Johnson & Johnson and its affiliates 2025. All rights reserved. US_ELP_XXXX_XXXXX